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bolus and infusion had a 36% rate of clinical restenosis (CR). Patients with-
out diabetes had a lower rate of restenosis whether receiving placebo ICR
~ 33%) or c7E3 (CR = 24%). In regression analysis. diabetes was the only
baseline clinical feature associated with an increased event rate (hazard ratio
1.44. P = 0.001). Among patients without diabetes. the relative risk of major
bleeding events was 2.6 times higher for those receiving c7E3 compared
to placebo 19.9% vs. 3.7%. respectively). This effect was doubled among
diabetics (12.9% vs. 2.2%, relative risk = 5.8). In conclusion, these data im-
portantly confirm the higher clinical restenosis among diabetics and demon-
strate a marked propensityto major bleeding events among diabetics treated
with potent platelet antagonists.
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ing In = 21) and prolonged perfusion balloon inflation (PPB; n = 22) as initial
bail-out therapy in failed PTCA. Core lab qualitative and quantitative angiog-
raphy analysis was possible in 40/43 patients.
Results.
Pre randomisation Post Randomisation
MLD{mm) % MLD(mm) % Success Recoil (mm)
5tent 1.1 ± 05 59 ± 17 2.2 ± 0.4 20 + 11 90% 032 ± 035
n ~ 21 19/21
PPB 12 ± 06 60 ± 18 1.5 ± 0.3 46 + 23 42% 096 ± 054
n ~ 19 8/19
P ns ns <0.001 <0.001 0002 <0.001
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1) Stenting was more effective as bail-out therapy (90% vs 42% P < 0.002),
especially in treating dissections of grade C or above: stent 11/12 (91%) vs
PBB (0/5 (0)% P < 0.0001).
2) Angiographic results with successful PPB were inferior to stenting: %
stenosis: 30.6 ± 20.2; MLD 1.9 ± 0.3 (p < 0.05 cf stent MLD) due to greater
recoil in the PPB group: PPB 0.66 ± 0.34 mm Ip < 0.05 cf stent recoil).
3) Stenting following failed PPB was successful in 9/10 attempts with equiv-
alent angiograms results to primary stent bail-out: % stenosis 24.8 ± 8.2;
MLD 2.5 ± 0.4 mm. but procedure time was longer 152.6 ± 53.0 mins v
114.8 ± 31.3 mins (p < 0.05).
Summary. This randomised multicentre study of bailout therapy in failed
PTCA confirms the benefit of stenting in improving immediate results by re-
ducing elastic recoil and sealing complex dissections. Crossover to stenting
following failed PPB gives angiographic results comparable to primary bail-
out stenting at the expense of increased lab time.
AG Results Reference (mm) MLD(mm) % Stenosis
Baseline 3.11 ± 0.47 0.66 ± 0.58 79 ± 19
Post 5tent 309 ± 0.50 3.01 ± 0.47 3 ± 12
Follow Up 3.01 ± 0.48 1.80 ± 0.91 40 ± 28
Simon G. Ray. Ian M. Penn. Donald R. Ricci. Jacques Barth, G.B. John Mancini.
Christopher E. Buller. Blair O'Neill. Christopher Foster. David Almond.
Charles Lazzam. Louis Roy, Gerald Barbeau. Vancouver Hospital and Health Sciences
Centre. Bri~sh Columbia, Canada
TASC II is a randomised multicentre study comparing the strategies of stent-
There was 1 acute stent thrombosis event (1.2%). Restenosis by 50% di-
ameter stenosis criteria was present in 17 of 49 lesions (35%) and 13 of 39
patients (34%).
Conclusions. (1) Stent Implantation in diffuse disease that is assisted by
IVUS is associated with acceptable procedure complication rate and a low
stent thrombosis rate despite the absence of post stent anticoagulation in
the majority of patients. (2) The restenosis rate of 35% appears to represent
an improvement over the reported restenosis rates for diffuse disease after
angioplasty or other devices.
Restenosis After Coronary Angioplasty is
Associated with the Activation Status of
Circulating Phagocytes Before Treatment
De novo Restenosis Total
5 (76) PTCA (73) 5 (61) PTCA (60) 5 {137} PTCA(133)
Death O{O%) 1 a a 0 1
MI 7 1 3 0 10 1
CABG 2 1 0 2 2 3
Repeat
Interven 3 5 5 4 10
Event free
Survival 64 (84%) 65189%) 57 (93%) 53(88%) 121 (88%) 118{89%)
The Trial of Angioplasty and Stents in Canada:
Clinical Outcome
Ian M. Penn, Robert I. Brown. Donald R. Ricci. David Almond. Jean F. Marquis.
John Webb. Blair O·Neili. Brendon Foley. Cindy Wong, Stephanie Monkman. TASC
Investigators. University of British Columbia, Vancouve" B.C., Canada
The trial of angioplasty and stents in Canada (TASC I) compared the strategy
of coronary artery stenting (S) to PTCA in de novo (de N ~ 149) and restenosis
(R ~ 121) lesions with a l' end point of angiographic restenosis and 2' end
point of event free survival at 6 months.
Results:
There was a reduction of clinical events in patients with restenosis le-
sions treated by stenting as compared to de novo lesions: 6.6% vs 15.8%
P ~ 0.094. There was an increased early (less < 40 days) infarct rate in the
stented patients due to stent thrombosis and a trend towards decreased
intervention in target lesions at 6 months (p = 0.088).
Conclusion: The strategies of coronary artery stenting in this study had
equivalent of event free survival to STRESS and Benestent in de novo lesions.
Patients who underwent stenting for restenosis lesions had an improved out-
come with only a 7% cardiac event rate at 6 months.
Patrick W 5erruys, Anneke Pietersma. Marcel Kofflard, L. Elly A. de Wit.
Thea Stijnen, Johan F. Koster, Wim Sluiter. Erasmus University. Rotterdam, NL
Background. The purpose of this study was to identify biological risk factors
for restenosis after PTCA. in order to predict the long-term outcome of PTCA
before treatment.
Methods and Results. To investigate whether blood granulocytes and
monocytes could determine luminal renarrowing after PTCA. several char-
acteristics of these phagocytes were assessed before angioplasty in 32 pa-
tients who underwent PTCA of one coronary artery and who had repeat an-
giograms at six months follow-up. The plasma levels 1L-1 p, TNF-a, IL-6. fib-
rinogen. C-reactive protein and LP(a) before angioplasty were assessed as
well. We found that the expression of the membrane antigens CD64. CD66
and CD67 by granulocytes was inversely associated with the luminal renar-
rowing normalized for vessel size (relative loss) at six months after PTCA.
while the production of IL-1 p by stimulated monocytes was positively asso-
ciated with the relative loss. Next. these univariate predictors were corrected
1935-371
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Results of Stent Implantation for Diffuse Coronary
Disease Assisted by Intravascular Ultrasound
Mechanism of Benefit of Stenting in Failed PTCA.
Final Results from the Trial of Angioplasty and
Stents In Canada (TASC II)
Luigi Maiello. Patrick Hall. Shigeru Nakamura. Simonetta Blengino. Leo Finci.
Giovanni Martini. Antonio Colombo. Columbus Hospital, Milan. Italy
The long term benefit of elective Palmaz-Schatz stent implantation for fo-
cal lesions in large vessels has been clearly delineated. The elective use of
stents in diffuse disease. however, has not been fully evaluated. This study
reports on the use of stents in 89 pts with 108 lesions (lesl with diffuse dis-
ease. Diffuse disease was defined as a lesion length longer than 20 mm. Af-
ter a successful angiographic result was obtained. intravascular ultrasound
(IVUS) was performed to confirm optimal stent expansion and lesion cover-
age and to guide further balloon dilation and stent implantation. The mean
age was 57 ± 10. Mean lesion length was 32 ± 6 mm. Vessel distribution was
51 LAD (47%). 45 RCA (42%). 10 LCX (9%). and 2 vein graft(2%) Lesion loca-
tion was 49 proximal (45%).52 mid (48%), and 7 distal 17%). 274 stents were
implanted (139 Palmaz-Schatz, 34 short (7 mm) Palmaz-Schatz, 48 Gianturco-
Roubin, and 53 Wiktor) for an average of 2.4 ± 1.4 stentsllesion. Procedure
success was achieved in 83 patients (93%). Procedure associated compli-
cations included 3 myocardial infarction (3%) and 3 emergency bypass (3%)
and 1 elective bypass (1 %). Following the procedure. 77 pts (93%) with 94
les were treated only with anti platelet therapy and no anticoagulation. An-
giographic follow up at 4-6 months was performed on 49 of the eligible 65
lesions (71 %). Baseline. final and follow up angiographic (AG) results are be-
low:
1935-351
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for the established clinical risk factors, dilation of the LAD, current smoking
and angina class.
Multiple linear regression analysis showed that luminal renarrowing could
be predicted reliably (R2 = 0.65; P < 0.0001) in this patients group on the
basis of the vessel dilated and only two biological risk factors that reflect
the activation status of blood phagocytes, i.e., the expression of C066 by
granulocytes and the production of IL-l,B by stimulated monocytes.
Conclusions. The results of the present study indicate that activated blood
granulocytes prevent luminal renarrowing after PTCA. while activated blood
monocytes promote restenosis. To validate this new finding further study in
an independent patients group is required.
Cardiac Allograft Vasculopathy
output (CO) were serially measured. In Group II, III and IV, all hearts were pre-
served with CCMP technique in hypothermia for 24 hours. Initial perfusion
pressure of CCMP was set to 5 mmHg with constant flow and the pressure
was monitored during the preservation. After all experimental protocol, tis-
sue water content (tWC) was measured. And ultrastructural findings of my-
ocardium and endothelial cells were evaluated. Recovery rate (post/pre;%)
of cardiac functions. CCM P pressure after 24 hours and tWC were as fol-
lows. In Group IV, ultrastructural findings showed minimal myocardial and
endothelial injury among preservation groups.
% sAP %AF %CF %CO CCMPpress. %tWC
Group I 99.7 ± 0.5 99.7 ± 0.5 99.7± 0.5 99.7± 0.5 (-) 82.2:1: 0.3
Group II 78.0 ± 8.2 52.8 ± 26.5 62.6:1:17.7 56.0±212 11.3:1:2.2 66.3±21.2·
Group III 87.1 ± 6.8 83.5± 10.7t 82.3± 12.0t 82.8± 8.9 t 8.2±1.3t 83.2:1: 2.9
Group IV 91.5 ± 4.2 89.2 ± 9.21 96.5±11.71 91.5± 5.41 5.2:1:0.21 84.7:1: 17
% Change in Vascular Wall Cell Proliferation
Tuesday, March 21, 1995,9:00 a.m.-11 :00 a.m.
Ernest N. Morial Convention Center, Hall E
Presentation Hour: 10:00 a.m,-11 :00 a.m.
This inhibitory effect of estradiol treatment on the mitogenic effect of IGF-I
and IL-6 on the vascular wall of the allograft supports previous studies show-
ing that accelerated coronary transplant arteriosclerosis in this model is in-
hibited by estrogen. These data speak to the use of hormone replacement
therapy in post menopausal women receiving a cardiac transplant.
Intrathymic Injection of Donor Splenocytes
Prolongs Rat Cardiac Allograft Survival but Does
not Inhibit Graft Arteriosclerosis
Yang T. Shin, David H. Adams. Lauri R. Wyner, Enver Akalin, Mohamed H. Sayegh.
Morris J. Karnovsky. Harvard Medical School, Boston, MA
GROUPS Inflammation % Vessels % Luminal Intima:Media
Diseased Occlusion Ratio
Control (A) severe 89 ± 1 64± 5 0.97 ± 0.33
Splenocyte only (e) moderate-severe 79 ± 8 57 ± 7 068:1: 0.16
ALS only (B) minimal 25 ± 7*' 8± 3·· 0.09 ± 0.04'
Splenocyte + ALS (D) minimal 27 ±4" 8 ± 3" 0.07:1: 0.03'
Chronic rejection, manifested by the development of graft arteriosclerosis.
remains the leading cause of late death in cardiac transplant recipients. Im-
munologic mechanisms have been implicated in both experimental and clini-
cal studies. yet the pathogenesis of chronic allograft rejection remains poorly
understood. Recent studies have shown that intrathymic (i.t.) injection of
donor cells or processed allo-MHC antigens with or without transient im-
munosuppression induces specific systemic T cell tolerance and prevents
acute allograft rejection in several experimental transplantation models. In
this study we examined the effects of i.t. injection of donor cells with or with-
out systemic anti-lymphocyte serum (ALS) on the development of chronic
rejection in the Lewis-to-F344 rat cardiac allograft model. Recipients were
divided into 4 groups: control group A was pre-treated with saline i.t., group
B was pre-treated with a one-time dose of ALS (1 mil via intraperitoneal in-
jection (i.p.). group C received donor (Lewis) splenocytes i.t. (2 x 106), and
group D received both the splenocytes i.t. and a one-time dose of ALS i.p.
two weeks prior to transplantation. Allografts were followed by daily palpa-
tion and graded from Q-4 (grade 0 = rejection, grade 4 = normal heartbeat).
Graft survival on post-op day 90 for all three experimental groups was 100%
vs. 33% for the control (n = 6/group). Moreover, mean heartbeat grade for
the three experimental groups (B = 2.83 ± 0.17, C = 2.0 ± 0.41. 0 = 2.67
± 0.21) was significantly higher (p < 0.01) than that of the control group (A
= 0.4 ± 0.24). Histologic and immunocytochemical analysis of 90-day old
grafts revealed the following results:
'p < 0.05 Group I vs II, t P< 0.05 Group II vs III. I p < 0.05 Group III vs IV
Conclusions: 1I CCMP with oxygenated UWs improved post-ischemic car-
diac functions and suppressed tissue edema in prolonged heart preser-
vation. 2) Addition of ETA antagonist suppressed damaged endothelium-
dependent vasoconstriction and also showed excellent functional recovery
and minimal myocardial injury.
'p < 0.02. "p < 0.003 vs. Control
1936-851
Chronic Estradiol Treatment of Rabbits with
Cardiac Allografts Attenuates Graft Vascular
Proliferation Induced by Insulin-like Growth
Factor-I (IGF-I) and Interleukin-6 (IL-6)
IGF-I (20 Itg/ml) INF-y (50 U/ml) IL.£ (50 U/ml)
Native
- Estradiol 175 ± 32 189 ± 43 162± 28
+ Estradiol 167 ± 42 143 ± 79 159 ± 36
Allograft
- Estradiol 328 ± 66 197 ± 56 366 ± 101
+ Estradiol 64± 12 116±41 72± 14
Mean ± SEM
Hong Lou, Teruaki Kodama, Nevin Katz, Marie Foegh. Georgetown University
Medical Center, Washington, DC
Male New Zealand White rabbits fed a 0.5% cholesterol diet (n = 13) re-
ceived a heterotopic cardiac allograft and cyclosporine (10 mg/kg/day) until
sacrifice 6 to 7 weeks later, at which time both the native and transplanted
hearts and aorta were harvested. Six of the rabbits were treated with estra-
diol 100 Itglkg/day i.m.. beginning 7 days prior to transplantation and con-
tinuing until sacrifice; the remaining seven rabbits served as controls and
received placebo. The native aorta as well as the aorta from the grafted
hearts were isolated and used for in vitro studies involving cytokine and
growth factor stimulated cell proliferation. Tritiated thymidine incorporation
is expressed as CPM/mg protein and the changes in cell proliferation are
expressed as % changes from the control (the unstimulated vessel). IGF-I
and IL-6 but not interferon-y (INF-y) significantly increased cell proliferation,
measured as 3H-thymidine incorporation. in explants from both native and
allograft vessels and significantly more so in the graft (p < 0.05). The mito-
genic effect of both IGF-I and IL-6 in the graft aorta, but not in that associated
with the native heart, was abrogated by chronic treatment with estradiol (p
< 0.02).
1936-831
Kenji Okada, Chojiro Yamashita, Morihito Okada. Masayoshi Okada. Kobe
University. Department ofSurgery. Division /I
Prolonged heart preservation by simple cold storage in University of Wis-
consin solution (UWs) and its deteriorative effect on endothelial function
have been problematic. We have studied whether continuous coronary
microperfusion (CCMP) technique with oxygenated UWs improves post-
ischemic functional recovery and addition of endothelin (ET) A receptor
antagonist (FR139317) reduces damaged endothelium-dependent vasocon-
striction. Twenty three isolated hearts of Japanese white rabbits were di-
vided into four groups according to preservation methods or modification of
UWs. Group I (control non-preserved). Group II (with original UWs), Group
III (with oxygenated UWs) and Group IV (with oxygenated UWs contained
10 mgll of FR139317). Cardiac functions of isolated hearts were evaluated
by Langendorf! apparatus. As pre and post-ischemic functional parameters,
systolic aortic pressure (sAP), aortic flow (AF), coronary flow (CF) and cardiac
\936-86\
1936-841 Efficacy of Endothelin A Receptor Antagonist(FR139317) for Long-term Heart Preservation
Conclusions: (1) The induction of systemic unresponsiveness with donor
splenocyte i.t. plus ALS i.p. or ALS i.p. alone markedly reduced inflamma-
tion and inhibited graft arteriosclerosis indicating that the immune response
and graft inflammation playa critical role in the pathogenesis of chronic al-
lograft rejection. (2) The donor cells 1.1. alone significantly prolonged graft
survival and prevented rejection as measured by functional criteria but did
not significantly inhibit graft inflammation or graft arteriosclerosis. These re-
sults suggest that partial suppression of the immune response without sig-
nificant inhibition of graft inflammation prolongs rat cardiac allograft survival
but does not prevent graft arteriosclerosis.
Plasma Fibrinogen Level Predicts Severity of
Intimal Thickening After Cardiac Transplantation
Clyde R. Meckel. Todd J. Anderson, Gilbert H. Mudge, Peter Ganz. Daniell. Simon.
Brigham and Women's Hospital, Boston. MA
Diffuse atherosclerosis is the primary reason for late graft failure after car-
diac transplantation. Because there is increasing evidence that imbalances
in the hemostatic and fibrinolytic pathways are associated with allogeneic re-
